GlassScriptPhysician profile
Albert K Hahm
NPI 1821208505
$3,540.12
in general payments reported to CMS, 2019-2025
23 companies · $586 in 2025
The $586 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $144 · 2021: $293 · 2022: $470 · 2023: $488 · 2024: $630 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,728.73 | 2019-2025 | |
| Pfizer INC. | $350.60 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $194.64 | 2019-2025 | Eohilia |
| Celgene Corporation | $179.34 | 2022-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.04 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $171.77 | 2019-2023 | Ocaliva |
| Janssen Biotech, INC. | $160.27 | 2019-2025 | Tremfya |
| Madrigal Pharmaceuticals | $73.02 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $61.87 | 2024-2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $61.39 | 2019 | |
| Merck Sharp & Dohme LLC | $50.33 | 2019-2023 | Dificid |
| Genzyme Corporation | $49.23 | 2023-2025 | |
| Ucb, INC. | $42.75 | 2019 | |
| Boston Scientific Corporation | $40.11 | 2019 | |
| Shionogi INC | $34.60 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $33.19 | 2024-2025 | Voquezna |
| Allergan, INC. | $25.77 | 2019 | |
| Gilead Sciences, INC. | $22.77 | 2019 | |
| Amgen INC. | $21.47 | 2025 | Uplizna |
| Alfasigma USA, INC. | $17.07 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $16.84 | 2021 | |
| Intra-Sana Laboratories | $14.81 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Vivus LLC | $13.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Hahm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.